Transaction · 0001835458-26-000004

Ragosa Mark

Ragosa Mark, CFO, reported an open-market or private sale at Kiniksa Pharmaceuticals International, plc involving 9114.000000 shares for an estimated $390534.90. Reported holdings after the transaction were 20817.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
KNSAKiniksa Pharmaceuticals International, plc
Filing timeFeb 11
Trade dateFeb 09, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$44.98
Pre-filing
1mo ago -5.1%1w ago -0.7%1d ago -4.2%
Returns since
7d +0.9%30d +1.8%90d +32.2%180d +70.1%1y +77.4%

KNSA price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
KNSA since 2026-02-11Filed 205 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001835458-26-000004
Class A Ordinary Share
Transaction date
Feb 09, 2026
Filed Feb 11, 2026, 09:38 PM · 2d delay
Shares
9.11k sh
$4.28k per share
Estimated value
-$39.0M
Computed from shares × price
Holdings after
20.8k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Large Holdings Reduction 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF FINANCIAL OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.

  2. F2

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $42.35 and $43.345. The price reported in this column reflects a weighted average sales price. Upon r…

  3. F3

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.35 and $44.18. The price reported in this column reflects a weighted average sales price. Upon re…

  4. F4

    The option is fully vested and exercisable.

Original filing · 0001835458-26-000004
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

KNSA